The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 16, 2021

Filed:

Mar. 14, 2017
Applicant:

Cynata Therapeutics Limited, Carlton, AU;

Inventors:

Igor Slukvin, Verona, WI (US);

Gene Uenishi, San Francisco, CA (US);

Derek Hei, Madison, WI (US);

Diana Drier, Madison, WI (US);

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/28 (2015.01); C12N 5/0775 (2010.01); C12N 5/07 (2010.01); C12N 5/0735 (2010.01); A61P 9/00 (2006.01); A61P 37/06 (2006.01); A61P 19/02 (2006.01); A61K 35/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0606 (2013.01); A61K 35/28 (2013.01); A61P 9/00 (2018.01); A61P 19/02 (2018.01); A61P 37/06 (2018.01); C12N 5/0662 (2013.01); C12N 5/0663 (2013.01); C12N 5/0665 (2013.01); C12N 5/0668 (2013.01); A61K 35/00 (2013.01); C12N 2500/02 (2013.01); C12N 2500/05 (2013.01); C12N 2501/115 (2013.01); C12N 2501/135 (2013.01); C12N 2501/155 (2013.01); C12N 2501/16 (2013.01); C12N 2501/22 (2013.01); C12N 2501/727 (2013.01); C12N 2501/999 (2013.01); C12N 2506/45 (2013.01); C12N 2533/52 (2013.01); C12N 2533/54 (2013.01);
Abstract

The invention relates to a method for producing a mesenchymal stem cell (MSC), the method comprising culturing a primitive mesoderm cell in a mesenchymal colony forming medium (M-CFM) comprising LiCl and FGF2, but excluding PDGF, under normoxic conditions for sufficient time for a mesenchymal colony to form, and culturing the mesenchymal colony adherently to produce the MSC, wherein the MSC has superior T-cell immunosuppressive properties relative to an MSC not produced in said M-CFM. The invention also relates to an MSC produced by the method, a population of MSCs produced by the method, a therapeutic composition comprising the MSC produced by the method, an M-CFM and an M-CFM in concentrated form, and method and uses of the MSC or population in treating a disease.


Find Patent Forward Citations

Loading…